There is also an urgent need to examine the performance of the C-SSRS in special populations, such as children and patients with dementia. The C-SSRS is widely utilized in clinical trials to assess suicide risk in children as young as 6 years old. Despite significant developmental differences in language and understanding of concepts such as death, an unmodified version of the instrument is often used for children from 6 to 17 years old. Moreover, the pediatric experience of the individuals administering the instrument to young children varies widely, and related operational challenges, such as the inclusion of caregiver input, have not been fully addressed. A pediatric version of the C-SSRS is available but has found only limited use, and no separate validity and reliability data are available on the use of any version of the C-SSRS for children younger than 12.